Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.03), $0.16 worse than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Goldman's Garrett sees investors dialing back tech exposure into H2
• MotorK names Roy Toren to board as Helen Protopapas resigns